Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Lanreotide (Somatuline® Autogel®) is recommended as an option for use within NHS Wales for the treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease. |
|||
|
|||
Medicine details |
|||
| Medicine name | lanreotide (Somatuline® Autogel®) | ||
| Formulation | 120 mg solution for injection | ||
| Reference number | 1988 | ||
| Indication | Treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease |
||
| Company | Ipsen Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1418 | ||
| NMG meeting date | 11/07/2018 | ||
| AWMSG meeting date | 12/09/2018 | ||
| Date of issue | 20/09/2018 | ||
| Date of last review | April 2022 | ||
| Further information This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||